Literature DB >> 9598110

Thymidine kinase expression. A marker for malignant cells.

M Hengstschläger1, M Pfeilstöcker, E Wawra.   

Abstract

The expression of thymidine kinase--an enzyme of the DNA precursor pathway--is strictly regulated during the normal cellular cycle, but is much higher and permanently expressed in malignant growing cells. Using a new cytofluorometric assay for thymidine kinase in single cells, we were able to discriminate between normal growing cells and virally transformed cells or lines derived from tumours. In material (blood and bone marrow) taken from leukaemia patients, we identified the leukaemic cells in a surplus of normal leucocytes. From cell cultures representing a tumour progression model, only the later, and malignant, stages showed enhanced fluorescence, whereas benign tumour cells looked normal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598110

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Authors:  Jeong Heo; Caroline J Breitbach; Anne Moon; Chang Won Kim; Rick Patt; Mi Kyung Kim; Yu Kyung Lee; Sung Yong Oh; Hyun Young Woo; Kelley Parato; Julia Rintoul; Theresa Falls; Theresa Hickman; Byung-Geon Rhee; John C Bell; David H Kirn; Tae-Ho Hwang
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

2.  Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer.

Authors:  Jun Su; Bo Yu; Chongguo Zhang; Peiqiang Yi; Huan Li; Cheng Xu; Lu Cao; Peizhan Chen; Min Li; Kunwei Shen; Jiayi Chen
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

3.  A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Authors:  Tae-Ho Hwang; Anne Moon; James Burke; Antoni Ribas; Joe Stephenson; Caroline J Breitbach; Manijeh Daneshmand; Naomi De Silva; Kelley Parato; Jean-Simon Diallo; Yeon-Sook Lee; Ta-Chiang Liu; John C Bell; David H Kirn
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

4.  Identification of potentially cytotoxic lesions induced by UVA photoactivation of DNA 4-thiothymidine in human cells.

Authors:  Olivier Reelfs; Peter Macpherson; Xiaolin Ren; Yao-Zhong Xu; Peter Karran; Antony R Young
Journal:  Nucleic Acids Res       Date:  2011-09-02       Impact factor: 16.971

5.  Thymidine kinase 1 upregulation is an early event in breast tumor formation.

Authors:  Melissa M Alegre; Richard A Robison; Kim L O'Neill
Journal:  J Oncol       Date:  2012-06-19       Impact factor: 4.375

6.  The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Authors:  Kelley A Parato; Caroline J Breitbach; Fabrice Le Boeuf; Jiahu Wang; Chris Storbeck; Carolina Ilkow; Jean-Simon Diallo; Theresa Falls; Joseph Burns; Vanessa Garcia; Femina Kanji; Laura Evgin; Kang Hu; Francois Paradis; Shane Knowles; Tae-Ho Hwang; Barbara C Vanderhyden; Rebecca Auer; David H Kirn; John C Bell
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 7.  Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.

Authors:  Janaina Fernandes
Journal:  Biomark Cancer       Date:  2016-07-28

Review 8.  Thionated organic compounds as emerging heavy-atom-free photodynamic therapy agents.

Authors:  Luis A Ortiz-Rodríguez; Carlos E Crespo-Hernández
Journal:  Chem Sci       Date:  2020-09-22       Impact factor: 9.825

9.  Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells.

Authors:  Tanya C Burch; Megan T Watson; Julius O Nyalwidhe
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 10.  The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Authors:  Caroline J Breitbach; John C Bell; Tae-Ho Hwang; David H Kirn; James Burke
Journal:  Oncolytic Virother       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.